A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Holdings (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Kangstem Biotech
- 12 Feb 2018 Planned number of patients changed from 206 to 194.
- 12 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 12 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2019.